Abstract
A Chlorella powder was screened using 52 in vitro assay systems for enzyme activity, receptor binding, cellular cytokine release, and B and T cell proliferation. The screening revealed a very potent inhibition of human protein tyrosine phosphatase (PTP) activity of CD45 and PTP1C with 50% inhibitory concentration (IC50) values of 0.678 and 1.56 μg/mL, respectively. It also showed a moderate inhibition of other PTPs, including PTP1B (IC50 = 65.3 μg/mL) and T-cell-PTP (114 μg/mL). Other inhibitory activities and their IC50 values included inhibition of the human matrix metalloproteinases (MMPs) MMP-1 (127 μg/mL), MMP-3 (185 μg/mL), MMP-7 (18.1 μg/mL), and MMP-9 (237 μg/mL) and the human peptidase caspases caspase 1 (300 μg/mL), caspase 3 (203 μg/mL), caspase 6 (301 μg/mL), caspase 7 (291 μg/mL), and caspase 8 (261 μg/mL), as well as release of the cytokines interleukin (IL)-1 (44.9 μg/mL), IL-2 (14.8 μg/mL), IL-4 (49.2 μg/mL), IL-6 (34.7 μg/mL), interferon-γ (31.6 μg/mL), and tumor necrosis factor-α (11 μg/mL) from human peripheral blood mononuclear cells. Chlorella also inhibited B cell proliferation (16.6 μg/mL) in mouse splenocytes and T cell proliferation (54.2 μg/mL) in mouse thymocytes. The binding of a phorbol ester, phorbol 12,13-dibutyrate, to its receptors was also inhibited by Chlorella with an IC50 of 152 μg/mL. These results reveal potential pharmacological activities that, if confirmed by in vivo studies, might be exploited for the prevention or treatment of several serious pathologies, including inflammatory disease and cancer.
Keywords
Get full access to this article
View all access options for this article.
